Jefferies Reiterates Buy Rating on UroGen Pharma (URGN)

Thu, 10 Sep 2026 02:43:11 -0400

Jefferies analyst Amin Makarem reiterated a Buy rating and $56.00 price target on UroGen Pharma (NASDAQ: URGN)

The analyst comments: “TYRA’s initial dabogratinib data are favorable for URGN, w/ the 57% 3mo CR at 60mg trailing Zusduri’s ~80% despite limited residual disease and pts w/ multiple marker lesions accounting for most nonresponders. Incomplete disease clearance suggests dabogratinib would more likely shift tx sequencing than materially reduce Zusduri’s addressable population. Up next, PIVOT-006 data in 2H26 represent the key competitive readthrough for URGN (stock +/-20%).

TYRA reported a 57% 3mo CR at the selected 60mg dose in SURF302, a ph.II evaluating dabogratinib against

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 08:00:00 -0400

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO^® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen’s only approved products, and the continued development of UroGen’s pipeline.

Up to 117,100 ordinary shares of UroGen are issuable upon the vesting and settlement of the

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 08:00:00 -0400

Up to 117,100 ordinary shares of UroGen are issuable upon the vesting and settlement of the

UroGen Pharma to Present at Upcoming Investor Conferences

Wed, 02 Sep 2026 08:00:00 -0400

PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September.

Wells Fargo 21^st Annual Healthcare Conference

Date / Time:	September 9th, at 3:00 PM ET
Format:	Fireside Chat
Location:	Boston, MA
Webcast Link:
Date / Time:	September 9th, at 3:00 PM ET
Format:	Fireside Chat
Location:	Boston, MA
Webcast Link:	IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure NAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies Thu, 20 Aug 2026 07:05:00 -0400 IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure NAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies Thu, 20 Aug 2026 07:05:00 -0400 IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure NAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies Thu, 20 Aug 2026 07:05:00 -0400 IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure NAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies Thu, 20 Aug 2026 07:05:00 -0400 IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure NAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies Thu, 20 Aug 2026 07:05:00 -0400 IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure NAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies Thu, 20 Aug 2026 07:05:00 -0400 IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure NAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies Thu, 20 Aug 2026 07:05:00 -0400 IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure NAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: Form 8-K UroGen Pharma Ltd. For: Aug 18 Thu, 20 Aug 2026 07:05:00 -0400 si-local-file:///var/storage/secattach/20260820/26952684.html Form 8-K UroGen Pharma Ltd. For: Aug 18 Thu, 20 Aug 2026 07:05:00 -0400 si-local-file:///var/storage/secattach/20260820/26952684.html UroGen strikes option deal with IntraGel, invests up to $7M Thu, 20 Aug 2026 07:00:31 -0400 UroGen Pharma Ltd. (Nasdaq: URGN) announced an Option and Research License Agreement and a related equity investment agreement with IntraGel Therapeutics, Ltd., granting UroGen access to IntraGel's SRGel biodegradable sustained-release drug delivery platform. Under the Option Agreement, UroGen receives a research license and exclusive options to license and develop up to three oncology products combining the SRGel platform with compounds designated by UroGen. UroGen also receives an exclusive option to license TumoCure, IntraGel's investigational cisplatin therapy for advanced head and neck cancer, contingent on IntraGel completing a Phase 2 clinical study. In connection with the agreement, UroGen will invest up to $7 UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline Thu, 20 Aug 2026 07:00:00 -0400 Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer PRINCETON, N.J., Aug. 20, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced a strategic Option and Research License Agreement (the Option Agreement) and a related equity investment agreement UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline Thu, 20 Aug 2026 07:00:00 -0400 Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer PRINCETON, N.J., Aug. 20, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced a strategic Option and Research License Agreement (the Option Agreement) and a related equity investment agreement

StreetInsider.com News Articles

Jefferies Reiterates Buy Rating on UroGen Pharma (URGN)

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Present at Upcoming Investor Conferences

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

Form 8-K UroGen Pharma Ltd. For: Aug 18

Form 8-K UroGen Pharma Ltd. For: Aug 18

UroGen strikes option deal with IntraGel, invests up to $7M

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline